Suprachoroidal Space Changes after Suprachoroidal Injection of Triamcinolone Acetonide for Uveitic Macular Edema

Purpose: To characterize suprachoroidal space (SCS) changes after suprachoroidal triamcinolone acetonide (TA) injection for uveitic macular edema and their impact on clinical outcomes. Methods: We reviewed medical records and enhanced-depth optical coherence tomography (EDI-OCT) images from 67 patients receiving suprachoroidal TA injections for uveitic macular edema to assess SCS visibility and thickness before and at 1, 3, and 6 months after treatment. We collected best-recorded visual acuity (VA), central subfield thickness (CST), intraocular pressure (IOP), and subfoveal choroidal thickness (SFCT), then employed repeated measures ANOVA and linear regression to determine changes over time, and the association of SCS visibility or expansion with VA and CST outcomes after treatment. Results: In patients with uveitic macular edema (mean age 59.6 years), the SCS is visualized in 90.1% of eyes, with baseline SCS thickness of 18.5 ± 1.1 μm. The SCS expanded by 6.7±0.2μm and 4.8±0.02μm at 1 and 3 months after TA (P=0.0001-0.016), but returned to baseline at 6 months (P=0.350). CST improved at months 1 and 6 (P=0.002–0.009), respectively. A visible hyporeflective SCS layer was associated with greater CST improvements at 1 month (P=0.036) and less CST change at 6 months (P<0.001). Early SCS expansion at 1 month was also associated with worse CST outcomes at 6 months (R2=0.482, P=0.004). Conclusions: Eyes receiving suprachoroidal TA injections demonstrate macular SCS expansion on OCT, which may be associated with earlier anatomic improvements but less durability.

Authors

Institutions

Publication Details

Journal
Retina
Published
2026-11-19
DOI
https://doi.org/10.1097/iae.0000000000005064
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Suprachoroidal Space Changes after Suprachoroidal Injection of Triamcinolone Acetonide for Uveitic Macular Edema

Kevin C. Choy, Sina Farsiu, Sean Chang, Glenn C. Yiu et al.
Retina
Ocular Diseases and Behçet’s Syndrome
article

Suprachoroidal Space Changes after Suprachoroidal Injection of Triamcinolone Acetonide for Uveitic Macular Edema

Kevin C. Choy, Sina Farsiu, Sean Chang, Glenn C. Yiu, Kareem Moussa, Ah-Ram Hong, Yevgeniy Sazhnyev, Parisa Emami-Naeini, Neha Sarabu
article en

Abstract

Purpose: To characterize suprachoroidal space (SCS) changes after suprachoroidal triamcinolone acetonide (TA) injection for uveitic macular edema and their impact on clinical outcomes. Methods: We reviewed medical records and enhanced-depth optical coherence tomography (EDI-OCT) images from 67 patients receiving suprachoroidal TA injections for uveitic macular edema to assess SCS visibility and thickness before and at 1, 3, and 6 months after treatment. We collected best-recorded visual acuity (VA), central subfield thickness (CST), intraocular pressure (IOP), and subfoveal choroidal thickness (SFCT), then employed repeated measures ANOVA and linear regression to determine changes over time, and the association of SCS visibility or expansion with VA and CST outcomes after treatment. Results: In patients with uveitic macular edema (mean age 59.6 years), the SCS is visualized in 90.1% of eyes, with baseline SCS thickness of 18.5 ± 1.1 μm. The SCS expanded by 6.7±0.2μm and 4.8±0.02μm at 1 and 3 months after TA (P=0.0001-0.016), but returned to baseline at 6 months (P=0.350). CST improved at months 1 and 6 (P=0.002–0.009), respectively. A visible hyporeflective SCS layer was associated with greater CST improvements at 1 month (P=0.036) and less CST change at 6 months (P<0.001). Early SCS expansion at 1 month was also associated with worse CST outcomes at 6 months (R2=0.482, P=0.004). Conclusions: Eyes receiving suprachoroidal TA injections demonstrate macular SCS expansion on OCT, which may be associated with earlier anatomic improvements but less durability.

Retina
Duke University (US), University of California, Davis (US)
Ocular Diseases and Behçet’s Syndrome
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon